uPA/uPAR/PAI与消化系统肿瘤

uPA/uPAR/PAI and digestive system tumors

消化系统肿瘤在我国的肿瘤发病率中占第1位。从尿激酶型纤溶酶原激活物受体(urokinase plas-minogen activator receptor,uPAR)首次被描述为尿激酶型纤溶酶原激活物(urokinase plasminogen activator,uPA)链的细胞表面高亲和性激活剂以来,越来越受到研究者的关注。研究表明:uPA,uPAR及尿激酶型纤溶酶原激活物抑制剂(urokinase plasminogen activator inhibitor,PAI)与消化系统肿瘤侵袭和转移密切相关。本文对uPA,uPAR及PAI与胃癌、食管癌、结肠癌、肝癌、胰腺癌等侵袭与转移的关系进行综述。

In cancer patients of our country,the incidence ratio of digestive system tumor is on the top one.Since urokinase plasminogen activator receptor （uPAR） has been described as urokinase plasminogen activator （uPA） chain of cell-surface and high-affinity activator,it has been attracted attention by researchers.Recent studies have shown that uPA,uPAR and urokinase plasminogen activator inhibitor （PAI） is closely related to invasion and metastasis of the digestive system tumor.This reviewed focus on uPA,uPAR and PAI invasion and metastasis in gastric cancer,esophageal cancer,colon cancer,liver cancer and pancreatic cancer.